• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

制药公司参与活动对处方决策的影响:对英国罕见病药物开方者的试点调查。

Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers.

机构信息

University of Leicester Business School, Leicester, UK.

Medialis Limited, 13 Horse Fair, Banbury, Oxfordshire, OX16 0AH, UK.

出版信息

Pharmaceut Med. 2020 Apr;34(2):127-134. doi: 10.1007/s40290-019-00323-x.

DOI:10.1007/s40290-019-00323-x
PMID:32048216
Abstract

INTRODUCTION

Traditionally, the pharmaceutical industry has used 'promotional personal engagement' activities, which involve interactions between sales forces and prescribers, in order to generate 'sales'-or prescriptions-of their new medicinal product(s). There appears to be now a favouring of 'non-personal engagement' (external information sources or activities existing outside the direct control of the company) and 'non-promotional personal engagement' activities (focused around creating peer-to-peer relationships between prescribers and pharmaceutical physicians).

OBJECTIVES

The purpose of this study was to examine the influence of non-personal engagement and non-promotional personal engagement activities on the prescribing habits of British healthcare professionals, using the traditional promotional personal engagement activities as a comparator.

METHODS

A questionnaire was distributed to 122 prescribers (physicians, nurses and pharmacists) working with two selected products for pulmonary arterial hypertension. The participants were asked to rate the influence that the listed activities had on their decision to prescribe each of the two products using a scale of 0-10, where 0 = 'no influence' and 10 = 'most important influence'.

RESULTS

Of the 122 targeted healthcare professionals who received the questionnaire, 34 (27.9%) responded within the 2-week time limit (24 physicians, 5 nurse prescribers and 5 pharmacists). The findings of the survey had a confidence level of 90% and a margin of error of 12%, given that 34 of 122 people responded. All proposed activities were scored by the respondents as having some influence on their prescribing. Personal engagement activities are effective for influencing prescribing, but non-promotional personal engagement activities may be more influential than promotional personal engagement activities. Furthermore, non-personal engagement activities may be more effective in influencing prescriptions of a product than either non-promotional or promotional personal engagement activities.

CONCLUSIONS

All personal engagement activities affect HCP prescribing behaviours; however, they appear to be more influential when performed on a non-promotional basis by representatives of the company's medical department.

摘要

简介

传统上,制药行业一直采用“促销个人互动”活动,这些活动涉及销售队伍和处方医生之间的互动,以促进其新产品的“销售”或处方。现在似乎更倾向于“非个人互动”(外部信息来源或公司直接控制之外的活动)和“非促销个人互动”活动(专注于在处方医生和制药医生之间建立同行关系)。

目的

本研究旨在考察非个人互动和非促销个人互动活动对英国医疗保健专业人员处方习惯的影响,将传统的促销个人互动活动作为比较。

方法

向 122 名从事肺动脉高压两种选定产品的处方医生(医生、护士和药剂师)分发了一份问卷。参与者被要求使用 0-10 的评分标准(0=“无影响”,10=“最重要的影响”)来评估列出的活动对他们决定开两种产品的每种产品的影响。

结果

在收到问卷的 122 名目标医疗保健专业人员中,有 34 名(27.9%)在两周的时间限制内做出了回应(24 名医生、5 名护士处方医生和 5 名药剂师)。调查结果的置信水平为 90%,误差幅度为 12%,因为有 34 人做出了回应。所有提出的活动都被受访者评为对他们的处方有一定影响。个人互动活动对处方有影响,但非促销个人互动活动可能比促销个人互动活动更有影响力。此外,非个人互动活动可能比非促销或促销个人互动活动更有效地影响产品的处方。

结论

所有个人互动活动都影响 HCP 的处方行为;然而,当由公司医疗部门的代表以非促销的方式进行时,它们似乎更有影响力。

相似文献

1
Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers.制药公司参与活动对处方决策的影响:对英国罕见病药物开方者的试点调查。
Pharmaceut Med. 2020 Apr;34(2):127-134. doi: 10.1007/s40290-019-00323-x.
2
Influence of pharmaceutical promotion on prescribers in Jordan.约旦的医药推广对处方医生的影响。
Int J Clin Pharm. 2020 Apr;42(2):744-755. doi: 10.1007/s11096-020-01006-3. Epub 2020 Mar 5.
3
Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples.制药营销策略对黎巴嫩医生处方模式的影响:伦理、礼品与样品
BMC Health Serv Res. 2019 Jan 30;19(1):80. doi: 10.1186/s12913-019-3887-6.
4
The attitude and acceptability towards medical promotional tools and their influence on physicians' prescribing practices in Jordan and Iraq: a cross-sectional study.约旦和伊拉克的医生对医疗促销工具的态度和接受程度及其对处方行为的影响:一项横断面研究。
BMC Health Serv Res. 2022 Jan 25;22(1):105. doi: 10.1186/s12913-022-07525-1.
5
Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.医生与制药行业(总体而言)以及销售代表(具体而言)之间的互动及其与医生态度和处方习惯的关联:一项系统综述。
BMJ Open. 2017 Sep 27;7(9):e016408. doi: 10.1136/bmjopen-2017-016408.
6
Perceptions and Attitudes of Egyptian Health Professionals and Policy-Makers towards Pharmaceutical Sales Representatives and Other Promotional Activities.埃及卫生专业人员和政策制定者对药品销售代表及其他促销活动的认知与态度
PLoS One. 2015 Oct 16;10(10):e0140457. doi: 10.1371/journal.pone.0140457. eCollection 2015.
7
A quantitative insight of the interactions of prescribers with pharmaceutical organization's representatives in clinical settings of Karachi.对卡拉奇临床环境中开处方者与制药公司代表互动情况的定量洞察。
Integr Pharm Res Pract. 2019 Jul 4;8:75-83. doi: 10.2147/IPRP.S196318. eCollection 2019.
8
Drug promotional activities in Nigeria: impact on the prescribing patterns and practices of medical practitioners and the implications.尼日利亚的药品促销活动:对医生处方模式和行为的影响及启示
Hosp Pract (1995). 2018 Apr;46(2):77-87. doi: 10.1080/21548331.2018.1437319. Epub 2018 Feb 20.
9
Perceptions of the provision of drug information, pharmaceutical detailing and engagement with non-personal promotion at a large physicians network: a mixed-methods study.大型医师网络中对药品信息提供、药品推销以及非个人促销活动的看法:一项混合方法研究。
BMJ Open. 2021 Jan 18;11(1):e041098. doi: 10.1136/bmjopen-2020-041098.
10
Influence of Medical Representatives on Prescribing Practices in Mekelle, Northern Ethiopia.医学代表对埃塞俄比亚北部默克莱地区处方行为的影响。
PLoS One. 2016 Jun 15;11(6):e0156795. doi: 10.1371/journal.pone.0156795. eCollection 2016.

引用本文的文献

1
Behavioral Components and Context of Antimicrobial Prescription in a Tertiary Hospital in Portugal.葡萄牙一家三级医院抗菌药物处方的行为成分与背景
Antibiotics (Basel). 2023 Jun 8;12(6):1032. doi: 10.3390/antibiotics12061032.
2
Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument.医学事务制药医师价值(MAPPval)工具的开发和验证。
Pharmaceut Med. 2022 Feb;36(1):47-57. doi: 10.1007/s40290-021-00413-9. Epub 2022 Jan 7.

本文引用的文献

1
Evolving role of pharmaceutical physicians in medical evidence and education.制药医师在医学证据与教育方面不断演变的角色。
Adv Med Educ Pract. 2018 Nov 2;9:777-790. doi: 10.2147/AMEP.S175683. eCollection 2018.
2
Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.欧洲的阳光政策与阴暗面:九个欧洲国家向卫生专业人员披露制药业付款情况。
Int J Health Policy Manag. 2018 Jun 1;7(6):504-509. doi: 10.15171/ijhpm.2018.20.
3
Off-label use of orphan medicinal products: a Belgian qualitative study.
罕见病药品的超说明书用药:一项比利时的定性研究。
Orphanet J Rare Dis. 2016 Oct 28;11(1):144. doi: 10.1186/s13023-016-0507-y.
4
Everything you need to know about the Sunshine Act.关于《阳光法案》你需要了解的一切。
BMJ. 2013 Jul 26;347:f4704. doi: 10.1136/bmj.f4704.
5
Pharmaceutical representatives do influence physician behaviour.
Fam Pract. 2009 Jun;26(3):169-70. doi: 10.1093/fampra/cmp033.
6
Drug reps and the academic medical center: a case for management rather than prohibition.
Perspect Biol Med. 2008 Spring;51(2):251-60. doi: 10.1353/pbm.0.0012.
7
Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study.经常会见制药行业代表的全科医生特征:全国性横断面研究。
BMJ. 2003 May 31;326(7400):1178-9. doi: 10.1136/bmj.326.7400.1178.
8
PRODIGY: implementing clinical guidance using computers.PRODIGY:利用计算机实施临床指南。
Br J Gen Pract. 1998 Sep;48(434):1552-3.
9
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.持续静脉输注依前列醇(前列环素)与常规疗法治疗原发性肺动脉高压的比较。
N Engl J Med. 1996 Feb 1;334(5):296-301. doi: 10.1056/NEJM199602013340504.
10
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.
Ann Intern Med. 1990 Apr 1;112(7):485-91. doi: 10.7326/0003-4819-112-7-485.